Confronted with the high demand but short supply of the COVID-19 antivirals, Creative Biolabs supports the development of anti-SARS-CoV-2 therapeutics with full-scale antibody discovery and protease inhibitor evaluation services.
February 21, 2022 /MarketersMEDIA/ —
Though two COVID-19 antiviral pills against at-risk individuals were granted emergency use authorization by FDA in late December, it's pointed out that the discovery and production of COVID-19 antivirals is still a big challenge, especially during the Omicron surge. As a world-leading biotech company that accumulated extensive experience from the previous MERS epidemic, Creative Biolabs is aware of the mission of obligations and responsibilities to be a part of developing effective anti-SARS-CoV-2 therapeutics, especially in the process of discovery and evaluation of antiviral drugs.
One of the FDA-authorized COVID-19 antiviral pills for emergency use is a protease inhibitor. Protease inhibitors, which can block the activity of enzymes that are necessary for the entry of the coronavirus into cells or viral replication, have been recognized as promising drug targets for the treatment of COVID-19. To help researchers discover and validate potent inhibitors for SARS-CoV-2 protease, Creative Biolabs provides protease assays to accelerate the development of COVID-19 therapeutics. Based on its evaluation platforms for SARS-CoV-2 drugs, a wide range of protease assays, including FRET-based assay, dose-response titration, cellular cytotoxicity test, and viral yield reduction (VYR) assay are available at Creative Biolabs for faster SARS-CoV-2 protease inhibitor detection and evaluation.
Considering that antiviral pills would lose their major efficacy of stopping viral replication after the first five-day onset of COVID-19 symptoms, monoclonal antibodies are still the key treatments for at-risk patients.
A researcher at Creative Biolabs indicated, "Monoclonal antibodies would be the only treatment in the shortage of antiviral pills, while some antibodies are becoming ineffective against Omicron. So we have to develop more and novel antibodies that can neutralize the coronavirus and render it noninfectious." Fortunately, the native SARS-CoV-2 CR3022 antibody still displays a high affinity for the receptor-binding domain (RBD) of the SARS-CoV-2 Omicron variant, suggesting that antibodies derived from it can still potentially neutralize the Omicron variant.
ACE2 (angiotensin converter enzyme 2) was identified as a significant cellular entry receptor before the SARS-CoV-2 infection, so it's the promising target for the treatments of SARS-CoV-2. Having been dedicated to the antibody market for decades, Creative Biolabs has built neutralizing antibody (nAb) platforms to provide services for SARS-CoV-2 ACE2-based peptide development, helping decrease the attrition rate of peptide candidates in the peptide drug discovery and development of SARS-CoV-2 therapeutics.
About Creative Biolabs
Creative Biolabs is a prestigious service provider for global researchers working for drug discovery. Except for being an expert in the discovery and evaluation of SARS-CoV-2 antibody, protease inhibitor, and peptide drugs, Creative Biolabs has extended comprehensive and high-quality COVID-19 supporting services to vaccine design and in vitro diagnostic services.
For more information, please visit https://sars-cov-2.creative-biolabs.com/.
Release ID: 89065043